High Q Technologies Expands Quantum Protein Analysis Platform For Alzheimer's Drug Discovery

High Q Technologies has expanded its quantum-enabled electron paramagnetic resonance (EPR) platform, Fathom, for accelerated drug discovery in Alzheimer's and neurodegenerative diseases by capturing multiple protein configurations simultaneously. The company has partnered with contract research organization Creative Biostructure to broaden global access to the technology.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.